We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

137 hedge funds and large institutions have $2.02B invested in China Biologic Products Holdings, Inc. in 2017 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $10.5M | Put options by funds: $2.37M

1% less capital invested

Capital invested by funds: $2.04B → $2.02B (-$15.7M)

4% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 26

4% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 49

4% less funds holding

Funds holding: 143137 (-6)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
137
Holders Change
-6
Holders Change %
-4.2%
% of All Funds
3.41%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.1%
New
25
Increased
47
Reduced
49
Closed
26
Calls
$10.5M
Puts
$2.37M
Net Calls
+$8.09M
Net Calls Change
+$11.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
101
Vanguard Group
Pennsylvania
$452K
Prudential Financial
102
Prudential Financial
New Jersey
$429K
RFCA
103
R&F Capital Advisors
New York
$422K -$111K -1,040 -20%
ROTUOC
104
Regents of the University of California
California
$421K -$449K -4,200 -50%
Two Sigma Investments
105
Two Sigma Investments
New York
$355K +$378K +3,541 New
GPCM
106
Granite Point Capital Management
Massachusetts
$350K
NEI
107
Northwest & Ethical Investments
Ontario, Canada
$335K
FIM
108
Freedom Investment Management
Connecticut
$322K +$117K +1,092 +51%
Capital Fund Management (CFM)
109
Capital Fund Management (CFM)
France
$270K -$409K -3,828 -59%
HHC
110
Hutchin Hill Capital
New York
$240K +$256K +2,400 New
GCP
111
GSA Capital Partners
United Kingdom
$222K -$2.31M -21,622 -91%
VKH
112
Virtu KCG Holdings
New York
$219K -$218K -2,042 -48%
Legal & General Group
113
Legal & General Group
United Kingdom
$210K
CG
114
Clinton Group
New York
$209K -$1.06M -9,964 -83%
CG
115
Cutler Group
California
$194K -$7.36M -68,902 -97%
MC
116
Martin Currie
United Kingdom
$160K -$42.7K -400 -20%
OAM
117
Oppenheimer Asset Management
New York
$156K +$166K +1,555 New
FMT
118
First Mercantile Trust
Tennessee
$120K
Envestnet Asset Management
119
Envestnet Asset Management
Illinois
$110K -$1.8M -16,798 -94%
DI
120
DUMAC Inc
North Carolina
$93K
ST
121
Smithfield Trust
Pennsylvania
$57K -$3.21K -30 -5%
PA
122
Perceptive Advisors
New York
$24K
Victory Capital Management
123
Victory Capital Management
Texas
$22K +$1.07K +10 +5%
Barclays
124
Barclays
United Kingdom
$17K -$71.3K -667 -80%
US Bancorp
125
US Bancorp
Minnesota
$12K +$3.53K +33 +38%

CBPO Hedge Fund Activity: Q1 2017 in Review

137 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2017, worth a combined $2.02B — down 0.77% from $2.04B a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CBPO and 25 opened new positions — a net loss of 1 holder — while 49 trimmed existing stakes and 47 added.

The largest buyer was BlackRock, adding an estimated $141M. The largest seller was Capital World Investors, cutting an estimated $104M.

  • 137 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2017, down from 143 in Q4 2016.
  • Funds reported $2.02B of China Biologic Products Holdings, Inc. stock for Q1 2017, down 0.77% quarter-over-quarter.
  • 25 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2017 and 26 closed out, a net change of -1 holder.
  • The largest China Biologic Products Holdings, Inc. buyer in Q1 2017 was BlackRock, an estimated $141M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q1 2017 was Capital World Investors, an estimated $104M sold.

Based on aggregated 13F filings for Q1 2017.